Liposome-mediated gene transfer is currently sub-optimal tering an equivalent DNA dose in aliquots over a 1-3 day with respect to both the extent and duration of transgene period resulted in significantly lower gene expression and expression. We investigated whether simple changes in did not increase the duration of expression. Administration DNA dosing could enhance either of these outcomes.
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to reduced cAMP-mediated chloride secretion in epithelial cells. 1 This relates to the accumulation of viscous infected secretions, particularly in the lungs, although the pathogenetic sequence is presently unclear. With the cloning of the CFTR gene, 2 the insertion of a normal copy into epithelial cells of the lungs became a possibility. The relative ease of access to the lungs and the monogenic nature of this disease make it an attractive candidate for gene therapy.
Gene therapy for CF has reached the stage of clinical trials, both with respect to cationic liposomes and viral delivery systems. 3 Changes towards normal values for the characteristic chloride abnormality have been reported for both, but generally at low levels (approximately 20%). It is likely that gene transfer efficiency will need to be increased to obtain clinical benefit. Further, gene expression is transient, studies suggesting a peak during the first 1-3 days after administration, followed by a gradual decrease in activity over the next 1-3 weeks. 4 Strategies to increase either the level or duration of expression, or both, would be of obvious benefit. To this end novel vectors, both viral and nonviral, are being extensively studied. 5, 6 Further, it is clear that a number of potential biological extra-and intracellular barriers to gene transfer exist, [7] [8] [9] [10] [11] and ways to overcome these are being intensively investigated. While these improvements in gene transfer technology are awaited, we asked whether simple changes to existing clinical protocols might be able to increase expression levels.
Increasing the DNA dose in contact with the plasma membrane provides an obvious opportunity to increase gene transfer efficiency. The in vivo DNA dose-response relationship of the airways with respect to gene transfer is unclear, with human studies 4, 12 suggesting little improvement in gene transfer with increasing dose or indeed a reduction in effect. However, a formal in vivo dose-response curve for administration to the lung, to the best of our knowledge, has not been reported. Second, administering a further dose of DNA around the time of peak expression of a first administration may augment gene expression, and increase the duration of effect, analogous to standard pharmacological treatments. Studies have shown that repeated application of liposomemediated gene transfer to the lungs is feasible. 13, 14 Finally, contact time of the DNA-lipid complex with the surface epithelium has been shown to be an important variable determining gene transfer efficiency. 7, 11 Limited data in man have shown that during periods of sleep there is a significant reduction in the rate of mucociliary clearance. 15 This may in turn allow for improved contact with the epithelial surface, as well as increasing the residence time of the DNA within the conducting airways, both likely important variables affecting gene transfer. We have assessed whether any of these three simple measures are able to increase the level, or prolong the duration of gene expression in an in vivo model.
The plasmid pCF-1 CAT, which encodes the reporter gene chloramphenicol acetyl transferase under the control of a CMV promoter was complexed with Genzyme lipid 67 for all studies. All complexing reactions were carried out so that equal volumes of lipid 67 (1.2 mm) were added to the pDNA (4.8 mm; the calculation of the molarity of the pDNA was based upon the assumption that the molecular weight of nucleotides is 330 g per mole). All mice were female Balb C of between 10 and 15 weeks of age. Data are presented as mean (s.e.m.) for convenience. Differences between groups were assessed using the Student's t test and the null hypothesis rejected at P Ͻ 0.05.
The effect of increasing DNA dose on the magnitude of transgene expression in the lungs of mice was determined. Maximal transgene expression was provided by 160 g of DNA 1 day following administration ( Figure  1 ). Higher doses produced significantly (P Ͻ 0.05) lower expression. Further, the 160 g dose did not produce significantly greater expression than the 80 g dose at any time-point subsequent to day 1. However, expression levels from both doses remained significantly elevated above baseline at day 21 (80 g: 2.0 × 10 −7 CAT U/g protein, 160 g: 1.6 × 10 −7 CAT U/g protein). We then assessed whether the magnitude and duration of expression was related to preferential proximal or distal gene transfer. Following administration of 80 g of DNA, transgene expression was generally higher in the proximal tissues (trachea and first to third generation bronchi) than in the distal airways and parenchyma (Figure 2 ), although this did not reach statistical significance. No change in this pattern was seen over the time period of gene expression.
The effect of dividing the dose of complexed pDNA on the magnitude of transgene expression was assessed. The dose was divided such that animals in groups B, C and D received two doses of 80 g (100 l volume), whereas animals in group A received 160 g of pDNA in one administration (200 l volume). Animals in group A produced the highest levels of expression over the first 3 days following administration (Figure 3) . No additional increase in the magnitude of expression was provided by administering 80 g followed by a further 80 g at 24 (cohort B), 48 (cohort C) or 72 (cohort D) h later. Further, divided doses did not produce a significant increase in the duration of transgene expression (Figure 4 ). Finally, no significant difference was seen in transgene expression irrespective of the time of day of the administration of the complex ( Figure 5 ).
This study was designed to assess whether simple changes in the dosing of DNA-liposome complexes to the lungs in vivo could either increase the magnitude or duration of gene expression. Our findings suggest that a single application provides for maximal effect in comparison with divided doses, but does not prolong transgene expression.
Little information is available with respect to in vivo dose-response relationships using DNA-liposome complexes. One human study suggested that there may be a bell-shaped response with higher doses in the nasal epithelium relating to lower expression. 12 We speculate that this relationship relates to increasing gene transfer efficiency balanced by increasing toxicity at higher doses. While our study did not formally assess histological changes, macroscopic evidence for toxicity (characteristic purple-red macular patches) was clearly present in a dose-related manner, with the 320 g and 480 g doses producing particularly striking changes. It is worth noting that in our present study we kept the concentration of both the plasmid DNA and the liposome, and hence the final complex, constant with increasing DNA doses. Thus, an increase in the DNA dose produced a corresponding increase in complex volume administered. It is possible that the decrease in transgene activity relates to the increase in volume of the complex delivered. However, to increase the DNA dose while retaining a constant volume would have increased the concentration of the DNA-liposome complex, introducing a further variable well recognised to alter transfection efficiency. While the observed toxicity at higher doses is in keeping with previously reported data in this model using lipid 67, 16 a recent study has shown that the presence of unmethylated CpG islands within bacterial DNA also contributes to the pulmonary inflammation related to DNA-liposome complex administration. 17 Further, our recent clinical trial of administration of lipid 67-DNA complexes to the lungs of CF subjects also demonstrated a level of mild toxicity, at lipid doses which did not cause problems in the non-CF subjects. 18 Thus, our data suggest, that as for any conventional therapeutic agent, it will be important to assess dose-escalation studies in the target organ in man using the final therapeutic product. Liposomes are likely to be subject to similar limitations to those seen for adenoviral gene transfer. In the latter, dose-related inflammation likely relates to the response of T lymphocytes to adenoviral coat proteins. 19, 20 Conventional pharmaceutical approaches to increasing the duration of an agent's effect include the use of slowrelease preparations. By dividing the dose of DNA over a period of 24-72 h, we hoped to provide a continuous 'reservoir' for complex uptake into the pulmonary epithelium. No increase in either duration or magnitude of expression was achieved by administering the complexed plasmid DNA in divided doses. The absence of additive effect on maximal gene expression is unlikely to relate to toxicity, given that a single dose of 160 g produced greater expression than two 80 g administrations. Whether this relates to a group of cells particularly susceptible to transfection is only conjecture. However, by administering a second dose of plasmid DNA after 24-72 h, it is possible that an immune response to the transgene limits the expression from the second administration. Given the interval between the two administrations we believe this is unlikely to contribute significantly.
A study in man has suggested that mucociliary clearance is significantly slowed during periods of sleep. 13 If a similar phenomenon occurred in mice, it might be possible to increase the time that the complex is in contact with the respiratory epithelium. No significant difference in transgene expression regardless of the time of day that the complex was administered was seen. Whether this is because mice do not possess the same diurnal changes in mucociliary clearance shown in man is unknown, and thus does not rule out the possibility that such a strategy would be useful in humans.
In conclusion, simple changes in the way DNAliposome complexes are administered do not seem to have an effect on the level and duration of gene expression within the lungs.
